Get the Stockscreener App
6.3317
4.79%
+0.2817
Palisade Bio Inc stock is currently priced at $6.3317, with a 24-hour trading volume of 40,004.
It has seen a +4.79% increased in the last 24 hours and a +1,489% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.10 pivot point. If it approaches the $6.45 resistance level, significant changes may occur.
Previous Close:
$6.05
Open:
$5.94
24h Volume:
40,004
Market Cap:
$5.15M
Revenue:
-
Net Income/Loss:
$-12.30M
P/E Ratio:
-0.9845
EPS:
-6.4313
Net Cash Flow:
$-11.13M
1W Performance:
+28.60%
1M Performance:
+1,489%
6M Performance:
+1,072%
1Y Performance:
+298.74%
1D Range:
$5.94
$6.4461
52W Range:
$0.3602
$9.65
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
858-704-4900
Address
5800 Armada Drive, Suite 210, Carlsbad
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
GlobeNewswire Inc.
S&P 500 Edges Lower; PacBio Shares Plunge
Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Gold Moves Higher; Morgan Stanley Earnings Top Views
Benzinga
Dow Gains Over 100 Points; Bank of America Posts Upbeat Profit
Benzinga
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
GlobeNewswire Inc.
Palisade Bio Inc Stock (PALI) Financials Data
Palisade Bio Inc (PALI) Net Income 2024
PALI net income (TTM) was -$12.30 million for the quarter ending December 31, 2023, a +13.74% increase year-over-year.
Palisade Bio Inc (PALI) Cash Flow 2024
PALI recorded a free cash flow (TTM) of -$11.13 million for the quarter ending December 31, 2023, a +16.67% increase year-over-year.
Palisade Bio Inc (PALI) Earnings per Share 2024
PALI earnings per share (TTM) was -$1.81 for the quarter ending December 31, 2023, a +92.52% growth year-over-year.
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Neal James R | Director |
Feb 09 '24 |
Option Exercise |
0.00 |
10,920 |
0 |
10,920 |
| Trenschel Robert J. | Director |
Feb 08 '24 |
Option Exercise |
0.00 |
10,920 |
0 |
10,920 |
| Csimma Cristina | Director |
Feb 08 '24 |
Option Exercise |
0.00 |
12,800 |
0 |
12,862 |
| Diaz Stephanie | Director |
Feb 08 '24 |
Option Exercise |
0.00 |
12,800 |
0 |
12,800 |
| Finley John David | CEO, CFO, Director |
Feb 06 '24 |
Option Exercise |
0.00 |
6,642 |
0 |
91,291 |
| Jones Mitchell Lawrence | Chief Medical Officer |
Feb 06 '24 |
Option Exercise |
0.00 |
6,891 |
0 |
9,815 |
| Finley John David | CEO, CFO, Director |
Feb 06 '24 |
Buy |
0.47 |
10,000 |
4,692 |
84,649 |
| Williams Donald Allen | Director |
Jan 31 '24 |
Buy |
0.60 |
10,000 |
6,050 |
30,000 |
| Finley John David | CEO, CFO, Director |
Jan 31 '24 |
Buy |
0.56 |
10,000 |
5,590 |
74,649 |
| Finley John David | CEO, CFO, Director |
Jan 03 '24 |
Option Exercise |
0.00 |
1,309 |
0 |
64,649 |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
1.22%
Cap:
|
Volume (24h):